Short answer
CRISPR Therapeutics AG (CRSP) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). CRISPR Therapeutics reported financial results for quarter ended June 30, 2026.
CRISPR Therapeutics AG 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- CRISPR Therapeutics reported financial results for quarter ended June 30, 2026
- Business highlights and detailed financial figures contained in furnished Exhibit 99.1
- Disclosure furnished under Regulation FD, limiting Section 18 liability and automatic incorporation into other filings
Item EX-99.1 · Exhibit EX-99.1
- CASGEVY revenue reached $76 million, up 78% quarter-over-quarter and 151% year-over-year, strengthening commercial validation
- FDA approval for patients aged 2 and older expands potential eligibility by approximately 5,500 SCD or TDT patients
- Cash, equivalents, and marketable securities rose to $2,364.4 million, supported by $585.4 million convertible-note proceeds
- Net loss narrowed to $91.2 million from $208.5 million, while quarterly collaboration revenue reached $10.0 million
- CTX340 and CTX460 entered Phase 1 trials, broadening the clinical pipeline into refractory hypertension and alpha-1 antitrypsin deficiency
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CRISPR Therapeutics AG 8-K filings
Get the next CRSP 8-K as it lands
Follow CRSP for push alerts, or ask the research agent what this filing means.